IGF1-IGF1R signaling in tumor-associated macrophages regulates extracellular matrix organization in BRAF inhibitor-targeted melanoma Authors: Ya Luo, Linlin Liu, Xing Zhou, Jiao Yang, Min Tang, Wei Feng, Chunlan Du, Xiaobo Liu, Liu Yang, Fei Liu, Liqun Zhang Published: 2026 ABSTRACT Melanoma, particularly driven by activating mutations in the BRAF gene, has witnessed significant therapeutic advances through targeted therapies such as BRAF and MEK inhibitors. However, the development of acquired resistance remains a major clinical challenge, limiting long-term treatment efficacy. The tumor microenvironment (TME), especially tumor-associated macrophages (TAMs), plays a pivotal role in mediating immune evasion, angiogenesis, and drug resistance. Despite extensive research into TAM polarization and function, the precise molecular mechanisms underlying their contribution to therapy resistance remain incompletely understood. Here, we investigated the regulatory role of IGF1-IGF1R signaling in THP-1-derived macrophages and its impact on the sensitivity of co-cultured melanoma cells to the BRAF inhibitor PLX4032. We observed markedly upregulated IGF1 expression in both melanoma cells and THP-1-derived macrophages. Either IGF1R knockdown or pharmacological blockade of IGF1–IGF1R signaling in macrophages restrained the polarization of THP-1-derived macrophages. Both in vitro cellular assays and in vivo xenograft experiments verified that A375 cells pre-co-cultured with IGF1R-deficient macrophages were more sensitive to PLX4032 relative to those pre-co-cultured with IGF1R-proficient macrophages. Transcriptomic analysis reveals that IGF1-IGF1R signaling in THP-1-derived TAMs significantly regulates extracellular matrix (ECM) organization. Collectively, our results offer a new insight into IGF1-IGF1R signaling in THP-1-derived macrophages regulating ECM organization in TME and its potential role in indirectly modifying the tumor cells responsiveness to PLX4032.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s11010-026-05673-0. Introduction Melanoma is the most aggressive form of skin cancer, with approximately half of cases driven by activating mutations in the BRAF proto-oncogene, leading to constitutive activation of the MAPK signaling cascade [1, 2]. While the advent of targeted therapies, particularly BRAF and MEK inhibitors (BRAFi and MEKi), has dramatically improved survival rates for patients with BRAF-mutant melanoma, the emergence of intrinsic or acquired resistance limits durable responses. Resistance mechanisms are multifactorial, involving both intracellular adaptations within tumor cells and dynamic interactions with the surrounding tumor microenvironment (TME). The TME comprises a complex network of immune cells, fibroblasts, endothelial cells, and extracellular matrix (ECM) components that collectively influence tumor progression, metastasis, and response to therapy. Among these, tumor-associated macrophages (TAMs) are among the most abundant immune populations in solid tumors and exhibit profound plasticity in response to environmental cues [3]. The classically activated M1 macrophages, induced by interferon-gamma (IFN-γ) or pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs), produce high levels of pro-inflammatory cytokines such as IL-12 and exhibit anti-tumor activity [4]. In contrast, alternatively activated M2 macrophages downregulate major histocompatibility complex class II molecules and secrete immunosuppressive cytokines including IL-4, IL-10, and IL-13, which promote angiogenesis, metastasis, and tumor cell invasion [4]. In addition, the plasticity of macrophages is also reflected in their response to other components of the tumor microenvironment, such as POSTN [5] and ALK And LTK Ligand 1 (ALKAL1) [6]. In tumors resistant to BRAFi/MEKi, melanoma cells produce POSTN, which polarizes TAMs toward a tumor-cell-protective phenotype [5]. Actually, macrophages and the ECM maintain a close bidirectional regulatory relationship. On one hand, TAMs act as central drivers of ECM remodeling. Beyond secreting abundant matrix metalloproteinases (MMPs) including MMP2 and MMP9 to degrade the ECM, they also directly participate in the synthesis, maturation and deposition of collagen [7, 8]. For instance, TAMs facilitate collagen maturation by expressing key enzymes such as P4HA1 and PLOD1, and boost collagen crosslinking via secretion of enzymes like LOX and LOXL2, consequently elevating tissue stiffness [9, 10]. On the other hand, elevated matrix stiffness functions as a potent mechanical cue. Through mechanosensors including integrins and the Piezo1 ion channel, alongside mechanotransduction signaling mediators such as YAP/TAZ, Rho/ROCK and FAK, stiffened matrix reciprocally drives macrophage polarization toward a pro-tumorigenic M2-like phenotype and establishes a positive feedback loop [10]. These M2-like TAMs further remodel the ECM and construct an immunosuppressive tumor microenvironment by releasing multiple factors including TGF-β, IL-10 and CCL18 [10]. Thus, these TAMs exhibit remarkable functional heterogeneity and phenotypic plasticity, enabling them to polarize into distinct functional states in response to microenvironmental cues, especially ECM in TME [3]. Insulin-like growth factor 1 (IGF1) is a pleiotropic cytokine that regulates cell survival, proliferation, differentiation, and metabolism [11]. It signals primarily through the IGF1 receptor (IGF1R), a tyrosine kinase receptor that activates downstream effectors such as PI3K/AKT and MAPK/ERK. In the context of cancer, IGF1-IGF1R signaling has been implicated in tumor initiation, progression, and resistance to chemotherapy and targeted therapy [12]. Notably, both tumor cells and stromal cells can produce IGF1, enabling autocrine and paracrine signaling loops that sustain tumor growth and immune evasion [13]. In melanoma, elevated serum levels of IGF1 have been associated with poor prognosis and resistance to BRAF inhibitors [14]. Furthermore, our previous work demonstrated that IGF1 contributes to vascular remodeling in the TME, thereby promoting resistance to targeted therapy [15]. Accumulating evidence has demonstrated that insulin-like growth factor 1 receptor (IGF1R) signaling is a critical regulator of the pro-tumorigenic properties of tumor-associated macrophages (TAMs). Specific deletion or pharmacological inhibition of IGF1R in macrophages effectively impairs their tumor-promoting functions by reversing macrophage polarization from the immunosuppressive M2 phenotype to the pro-inflammatory and anti-tumor M1 phenotype [12, 16]. Multiple preclinical tumor models, including lung cancer, pancreatic cancer, breast cancer, and metastatic tumor systems, have verified that myeloid-specific IGF1R ablation remodels the tumor immune microenvironment, reduces the infiltration of immunosuppressive cells, and elevates intratumoral accumulation of cytotoxic CD8 [12]. Moreover, loss of IGF1R signaling in TAMs disrupts the bidirectional crosstalk between macrophages and tumor cells. Thus, IGF1-IGF1R signaling acts as a pivotal driver of TAM-dependent immune suppression and tumor progression, highlighting its potential as a promising immunotherapeutic target for tumor intervention. Here, we report that IGF1-IGF1R signaling in THP-1-derived macrophages promotes resistance to BRAF inhibitors by regulating ECM organization. By disrupting IGF1R expression in THP-1-derived macrophages, we observed impaired macrophages-mediated drug resistance, ECM remodeling, and restored sensitivity to BRAF inhibition. These findings highlight the potential of targeting IGF1-IGF1R signaling in TAMs as a novel therapeutic approach to enhance the efficacy of existing targeted therapies in melanoma. Materials and methods Cell culture and reagents Human monocytic THP-1 cells were purchased from Wuhan Pricella Biotechnology Co., Ltd. and maintained in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and 0.05 mM β-mercaptoethanol. Human melanoma cell lines A375, SKMEL28, and WM2664 were cultured in DMEM medium with 10% FBS and 1% antibiotics. To establish PLX4032-resistant A375 cell lines (A375R), A375 cells cultured in T25 tissue culture flasks were treated with 1 µM PLX4032, and this constant drug concentration was retained throughout successive cell passages. An aliquot of cells was collected at each passage for MTT assay to evaluate cellular sensitivity to PLX4032 until stable PLX4032 resistance was successfully induced in A375 cells. All cell lines were incubated at 37 °C in a humidified atmosphere containing 5% CO₂. Recombinant human IFNγ, IGF1, IL-4, and IL-13 were obtained from PeproTech. Phorbol 12-myristate 13-acetate (PMA) and lipopolysaccharide (LPS) were purchased from InvivoGen. The BRAF inhibitor PLX4032 (vemurafenib) was purchased from Selleck Chemicals (#S1267). Primary antibodies used for flow cytometry included FITC-conjugated anti-human CD68 (Biolegend, Cat. 333806), PE-conjugated anti-human CD206 (MMR) (Biolegend, Cat. 321106), and PE/Cyanine5-conjugated anti-human CD80 (Biolegend, Cat. 305210). Fixable viability dye eFluor510 was acquired from Invitrogen (Cat. 65-0866-14). Total RNA extraction was performed using RNAiso Plus (TaKaRa), and reverse transcription and quantitative PCR reagents were also obtained from TaKaRa. Macrophage polarization THP-1 cells were differentiated into macrophages (M0) by treating with 100 ng/mL PMA for 48 h. For polarization, M0 macrophages were stimulated with either IFNγ (20 ng/mL) plus LPS (10 pg/mL) for M1 polarization or IL-4 (20 ng/mL) plus IL-13 (20 ng/mL) for M2 polarization. Cell surface markers were analyzed by flow cytometry to confirm polarization status. Plasmid construction and lentiviral transduction Short hairpin RNAs (shRNAs) targeting IGF1R and a scrambled control sequence were synthesized by VectorBuilder (China) and cloned into the pLV-EGFP/Puro-U6 vector. Lentiviruses were produced by transient transfection of HEK293T cells and used to infect THP-1-derived macrophages. Stable knockdown clones were selected using puromycin. The target sequences were: shIGF1R#1: GTCTTCCATAGAAAGAGAAAT, shIGF1R#2: GCGCATGTGCTGGCAGTATAA, shIGF1R#3: CAAGGGCAATTTGCTCATTAA, Scramble_shRNA (shCTRL): CCTAAGGTTAAGTCGCCCTCG. Efficiency of IGF1R knockdown was confirmed by qRT-PCR and Western blotting. Immunohistochemistry and immunofluorescence staining Paraffin-embedded tissue sections were deparaffinized and subjected to antigen retrieval using EDTA buffer (pH 9.0) for 15 min at 95 °C. Sections were stained with primary antibodies against F4/80 (Invitrogen, #MA1-91124, 1:400) and Collagen IV (Abcam, #ab6586, 1:100) overnight at 4 °C. Secondary antibodies conjugated to Alexa Fluor 488 or 594 were applied for 60 min at room temperature. Nuclei were counterstained with DAPI. Images were captured using an Olympus SpinSR10 spinning disk confocal microscope. Animal experiments Six- to eight-week-old male BALB/c nude mice were purchased from Vital River Laboratory Animal Technology Co., Ltd. (Beijing). Genetically engineered mice with myeloid-specific IGF1R deletion (IGF1Rflox/flox; Lyz2-CreERT) and control littermates (IGF1Rflox/flox) were bred at Shanghai Model Organisms. All animals were housed under specific pathogen-free conditions and handled according to protocols approved by the Laboratory Animal Welfare and Ethics Committee of the Army Medical University. For in vivo experiments, A375 cells were “educated” by co-culturing with THP-1-derived M0 macrophages for three rounds (each round lasting 48 h). No PLX4032 was supplemented into the culture medium for the co-culture system. To verify the sensitivity of co-cultured A375 cells to PLX4032, each rounded of A375 cells after co-culturing were seeded in 96-well plate for MTS assay. Educated A375 cells (2 × 10⁶ cells in 100 µL PBS) were subcutaneously injected into the flank of nude mice. When tumors reached 100–150 mm³, mice were treated with PLX4032 (10 mg/kg) or vehicle every two days. Tumor volumes were measured regularly. Six- to eight-week-old male genetic mice were used for animal experiments. SMM102 melanoma cells were implanted into C57BL/6 mice with or without myeloid-specific IGF1R deletion. Treatment with PLX4032 or vehicle began when tumors reached 150 mm³. MTS assay Cell viability was assessed using the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega). Cells were seeded at 5,000 per well in 96-well plates and treated with serial dilutions of PLX4032 for 72 h. MTS reagent was added, and absorbance at 490 nm was measured using a SpectraMax i3x plate reader. IC₅₀ values were calculated using GraphPad Prism software. Western blot Cells cultured in 6-well plates were washed three times with ice-cold PBS following treatment. Cells were lysed on ice in 80–100 µL of RIPA lysis buffer (Beyotime) and scraped; the lysates were collected into 1.5-mL microcentrifuge tubes and incubated on ice for 30 min with intermittent vortexing (3–5 times). Lysates were centrifuged at 12,000 ×g and 4 °C for 15 min, and the supernatants were collected. Protein concentrations were determined using a BCA assay (Solarbio). Equal amounts of protein were mixed with 5× SDS loading buffer (4:1, v/v), boiled at 95 °C for 5 min, separated by SDS-PAGE, and transferred onto PVDF membranes. Membranes were blocked with QuickBlock™ Blocking Buffer for Western Blot (Beyotime) for 30 min at room temperature, incubated overnight at 4 °C with primary antibodies against GAPDH (AC001, ABclonal), IGF1 (ab9572, abcam), p-STAT1 (9177 S, CST), STAT1 (9172 S, CST), IFNγR2 (ab171081, abcam), β-actin (AC038, ABconal), p-ERK (4370, CST), ERK (4697, CST), IGF1Rβ (9750, CST), p-IGF1Rβ (3024, CST). After washing three times with TBST, and membranes were incubated with HRP-conjugated secondary antibodies (ABclonal) for 1 h at room temperature. Protein bands were visualized using enhanced chemiluminescence (ECL) and the grayscale values of bands were quantified using ImageJ software. Bioinformatics analysis After three rounds of co-culture, THP-1 derived macrophages including the TAMs_shCTRL (macrophage transduced with shRNA control) and TAMs_shIGF1R (macrophage transduced with IGF1R shRNA#3), A375 cells including A375_TAMs_shCTRL (A375 cells pre-co-cultured with TAMs_shCTRL) and A375_TAMs_shIGF1R (A375 cells pre-co-cultured with TAMs_shIGF1R) were collected. Each group had three replicates. Total RNA was extracted using Trizol reagent and quantified using Qubit and Qsep400. mRNA was enriched using oligo(dT) magnetic beads. The purified mRNA was randomly fragmented into short fragments, followed by first-strand and second-strand cDNA synthesis. After end repair, A-tailing, and adapter ligation, cDNA fragments were purified and PCR-amplified to construct the final cDNA library. Libraries were subjected to paired-end 150 bp (PE150) sequencing on the Illumina NovaSeq X Plus platform. Each sample was required to generate 6 Gb of clean data, with the data yield of every sample guaranteed to be no less than 95% of the target volume. Raw sequencing reads were quality-trimmed and filtered using fastp, mapped to the human reference genome via HISAT2, and gene expression was quantified with featureCounts, followed by FPKM normalization. Batch effect correction was performed using the ComBat algorithm embedded in the sva R package to eliminate technical variations across different sequencing batches. Differential gene expression analysis was implemented using DESeq2. Multiple testing correction was conducted with the Benjamini–Hochberg method to calculate the false discovery rate (FDR). Genes with FDR < 0.05 and |Log2(Fold Change)| ≥ 1 were identified as differentially expressed genes (DEGs). Functional enrichment analyses were performed based on the KEGG and Reactome databases. Statistical analysis All data are presented as mean ± standard deviation (SD). Sample sizes were n ≥ 3 unless otherwise stated. Comparisons between two groups were analyzed using Student’s t-test; multiple comparisons were evaluated by one-way ANOVA followed by Tukey’s post hoc test. Statistical significance was defined as ns, not significant, *P < 0.05, **P < 0.01 and ***P < 0.001. Analyses were performed using GraphPad Prism 8.0.1. Results IGF1 expression is elevated in PLX4032-treated melanoma cells and cytokine-polarized macrophages To assess the expression of IGF1 in melanoma cells under therapeutic stress, we first confirmed that A375 cells were sensitive to PLX4032, with an IC50 of 0.1867 µM after 72-hour exposure (Fig. 1A). Western blot analysis revealed that IGF1 protein expression increased significantly in A375 cells treated with low-dose PLX4032 (0.01–1 µM) compared to vehicle control (Fig. 1B). To further investigate the expression of IGF1 in drug resistant tumor cells, we generate a resistant model by culturing A375 cells continuously in 1 µM PLX4032, which resulted in the establishment of A375R cells (A375 cells resistant to 1µM PLX4032, IC50 > 10 µM, Fig. 1C). Western blot analysis exhibited higher phosphorylated ERK (p-ERK) levels and significantly elevated IGF1 expression in (Fig. 1D). Fig. 1IGF1 expression is elevated in PLX4032-treated melanoma cells and cytokine-polarized macrophages. A Viability of A375 cells treated with PLX4032 for 72 h. Data are presented as mean ± SD (n = 5), normalized to DMSO vehicle (set as 100%). B Western blot analysis of IGF1 protein expression in A375 cells treated with increasing concentrations of PLX4032 for 24 h. C Viability of PLX4032-resistant A375R cells (maintained in 1µM PLX4032) treated with PLX4032 for 72 h. Data are presented as mean ± SD (n = 5), normalized to DMSO vehicle (set as 100%). D Western blot analysis of IGF1, ERK, and p-ERK protein expression in parental A375 and A375R cells. E Morphological images of THP-1 cells and THP-1-derived M0 macrophages. F Relative CD68 mRNA expression in THP-1 cells and M0 macrophages. G Morphological images of THP-1-derived M1 and M2 macrophages. H–J Relative mRNA expression of CD68 H, CD80 I, and CD206 J in THP-1-derived macrophages. Data are presented as mean ± SD (n = 4). K Flow cytometry analysis of CD68⁺, CD80⁺, and CD206⁺ cell percentages in M0, M1, and M2 macrophages. Data are presented as mean ± SD (n = 3). L Relative mRNA expression of IGF1 in THP-1-derived macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test D, F, One-way ANOVA B, H–J and L and two-way ANOVA K. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant IGF1 expression is elevated in PLX4032-treated melanoma cells and cytokine-polarized macrophages. A Viability of A375 cells treated with PLX4032 for 72 h. Data are presented as mean ± SD (n = 5), normalized to DMSO vehicle (set as 100%). B Western blot analysis of IGF1 protein expression in A375 cells treated with increasing concentrations of PLX4032 for 24 h. C Viability of PLX4032-resistant A375R cells (maintained in 1µM PLX4032) treated with PLX4032 for 72 h. Data are presented as mean ± SD (n = 5), normalized to DMSO vehicle (set as 100%). D Western blot analysis of IGF1, ERK, and p-ERK protein expression in parental A375 and A375R cells. E Morphological images of THP-1 cells and THP-1-derived M0 macrophages. F Relative CD68 mRNA expression in THP-1 cells and M0 macrophages. G Morphological images of THP-1-derived M1 and M2 macrophages. H–J Relative mRNA expression of CD68 H, CD80 I, and CD206 J in THP-1-derived macrophages. Data are presented as mean ± SD (n = 4). K Flow cytometry analysis of CD68⁺, CD80⁺, and CD206⁺ cell percentages in M0, M1, and M2 macrophages. Data are presented as mean ± SD (n = 3). L Relative mRNA expression of IGF1 in THP-1-derived macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test D, F, One-way ANOVA B, H–J and L and two-way ANOVA K. *P < 0.05, **P < 0.01, ***P < 0.001, ns: not significant We next investigated IGF1 expression in macrophages derived from THP-1 cells. After PMA-induced differentiation into M0 macrophages, cells displayed typical morphology and high CD68 expression (Fig. 1E, F). Upon polarization, M1 macrophages showed increased CD80 expression, while M2 macrophages expressed higher levels of CD206 (Fig. 1G–J). Flow cytometry analysis confirmed these trends in protein levels (Fig. 1K and Fig. S1A–B). Notably, both M1 and M2 macrophages expressed IGF1, with M2 macrophages showing higher basal levels (Fig. 1L). Above results demonstrate that both melanoma cells and macrophages could secrete IGF1. IGF1 enhances macrophage polarization via IGF1R activation Given the dual expression of IGF1 in tumor and immune cells, we examined whether exogenous IGF1 influences macrophage polarization. Treatment of M0 macrophages with 100 ng/mL IGF1 led to phosphorylation of IGF1R and upregulation of IFNγR2, a key receptor in M1 polarization (Fig. 2A). When combined with IFNγ, anti-IGF1 antibody attenuated IFNγR2 expression and STAT1 phosphorylation, suggesting that IGF1 supports M1 polarization through autocrine signaling (Fig. 2B). Fig. 2IGF1 modestly promoted both M1 and M2 macrophage polarization. A Western blot analysis of p-IGF1R β, IGF1R β, and IFNγR2 expression in THP-1-derived M0 macrophages treated with IGF1 (100 ng/ml) for 48 h. B Western blot analysis of p-IGF1R β, IGF1R β, IGF1, p-STAT1, STAT1, and IFNγR2 expression in THP-1-derived macrophages treated with anti-IGF1 (1 ug/ml) and/or IFNγ (25 ng/ml). C, D Flow cytometry analysis of CD68, CD80 and CD206 expression in THP-1-derived macrophages with or without IGF1 (100 ng/ml) stimulation. E–G Mean fluorescence intensities (MFI) of CD68, CD80 and CD206 were analyzed. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test A, One-way ANOVA B, E–G. ***P<0.001, ns: not significant IGF1 modestly promoted both M1 and M2 macrophage polarization. A Western blot analysis of p-IGF1R β, IGF1R β, and IFNγR2 expression in THP-1-derived M0 macrophages treated with IGF1 (100 ng/ml) for 48 h. B Western blot analysis of p-IGF1R β, IGF1R β, IGF1, p-STAT1, STAT1, and IFNγR2 expression in THP-1-derived macrophages treated with anti-IGF1 (1 ug/ml) and/or IFNγ (25 ng/ml). C, D Flow cytometry analysis of CD68, CD80 and CD206 expression in THP-1-derived macrophages with or without IGF1 (100 ng/ml) stimulation. E–G Mean fluorescence intensities (MFI) of CD68, CD80 and CD206 were analyzed. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test A, One-way ANOVA B, E–G. ***P<0.001, ns: not significant Flow cytometric analysis showed that IGF1 treatment slightly enhanced the proportion of CD68⁺CD80⁺ (M1-like) and CD68⁺CD206⁺ (M2-like) cells (Fig. 2C, D) while the mean fluorescence intensity (MFI) of CD68, CD80 and CD206 shows no statistic difference (Fig. 2E–G), indicating that IGF1 promotes both polarization states, albeit modestly. Knockdown of IGF1R impairs THP1-derived TAMs-mediated drug resistance To determine the functional role of IGF1R in macrophages, we generated IGF1R-knockdown THP-1-derived macrophages using lentiviral shRNA. shIGF1R#3 showed the highest efficiency in reducing IGF1R mRNA levels (Fig. 3A). IGF1R deficiency led to decreased IFNγR2 expression in M0 macrophages (Fig. 3B) and altered expression of polarization markers in both M1 and M2 subsets (Fig. 3C–J). Additionally, pharmacological inhibition of IGF1R via BMS-754,807 markedly downregulated the expression of IFNγR2, CD68, CD80, and CD206 in THP-1-derived M0 macrophages (Fig. S2A–D). Specifically, CD80, SPP1, and CXCL9 were downregulated in M1 macrophages, while SPP1 and CXCL9 were reduced in M2 macrophages. Fig. 3Knockdown of IGF1R in THP-1-derived macrophages impairs their polarization and ability to promote melanoma progression. A Relative IGF1R mRNA expression in THP-1 cells transfected with shRNA lentivirus. Data are presented as mean ± SD (n=3). B–J Relative IFNγR2 B, CD68 C, D, CD80 E, CD206 H, SPP1 F, I and CXCL9 G, J mRNA expression in THP-1-derived macrophages transfected with shRNA lentivirus. K–M MTT assay assessing viabilities of SKMEL28 K, WM2664 L, and A375 M melanoma cells treated with PLX4032 following co-culture with M0 macrophages transfected with shCTRL or shIGF1R. The IC50 value of SKMEL28 cells was 0.81 μM; the IC50 values for SKMEL28 pre-co-cultured with M0 shCTRL 1–3 were 1.8 μM, >10 μM and >10 μM, versus 0.86 μM, 0.63 μM and 0.57 μM for cells pre-co-cultured with M0 shIGF1R 1–3. The IC50 of WM2664 cells was 0.98 μM, with values of 4.1 μM, >10 μM, >10 μM in the M0 shCTRL pre-co-culture groups and 1.6 μM, 3.4 μM, 4.5 μM in the M0 shIGF1R pre-co-culture groups. For A375 cells, the baseline IC50 was 0.19 μM, accompanied by IC50 values of 0.18 μM, >10 μM, >10 μM in the M0 shCTRL pre-co-culture group and 0.06 μM, 0.20 μM, 0.13 μM in the M0 shIGF1R pre-co-culture groups. N Tumor volumes of A375 cells xenografted in nude mice, with or without prior co-culture with M0 shCTRL or M0 shIGF1R macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test B–J, One-way ANOVA A, N. *P<0.05, **P<0.01, ***P<0.001, ns: not significant Knockdown of IGF1R in THP-1-derived macrophages impairs their polarization and ability to promote melanoma progression. A Relative IGF1R mRNA expression in THP-1 cells transfected with shRNA lentivirus. Data are presented as mean ± SD (n=3). B–J Relative IFNγR2 B, CD68 C, D, CD80 E, CD206 H, SPP1 F, I and CXCL9 G, J mRNA expression in THP-1-derived macrophages transfected with shRNA lentivirus. K–M MTT assay assessing viabilities of SKMEL28 K, WM2664 L, and A375 M melanoma cells treated with PLX4032 following co-culture with M0 macrophages transfected with shCTRL or shIGF1R. The IC50 value of SKMEL28 cells was 0.81 μM; the IC50 values for SKMEL28 pre-co-cultured with M0 shCTRL 1–3 were 1.8 μM, >10 μM and >10 μM, versus 0.86 μM, 0.63 μM and 0.57 μM for cells pre-co-cultured with M0 shIGF1R 1–3. The IC50 of WM2664 cells was 0.98 μM, with values of 4.1 μM, >10 μM, >10 μM in the M0 shCTRL pre-co-culture groups and 1.6 μM, 3.4 μM, 4.5 μM in the M0 shIGF1R pre-co-culture groups. For A375 cells, the baseline IC50 was 0.19 μM, accompanied by IC50 values of 0.18 μM, >10 μM, >10 μM in the M0 shCTRL pre-co-culture group and 0.06 μM, 0.20 μM, 0.13 μM in the M0 shIGF1R pre-co-culture groups. N Tumor volumes of A375 cells xenografted in nude mice, with or without prior co-culture with M0 shCTRL or M0 shIGF1R macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Student’s t-test B–J, One-way ANOVA A, N. *P<0.05, **P<0.01, ***P<0.001, ns: not significant To further explore the role of THP-1-derived macrophages on tumor development, we co-cultured the THP-1-derived macrophages and melanoma cells, in which THP-1-derived TAMs were formed. Following co-culturing, melanoma cells (SKMEL28, WM2664, A375) pre-exposed to M0 shCTRL macrophages progressively developed less sensitive to PLX4032, and displayed resistance to PLX4032 after successive two rounds of co-culture (Fig. 3K–M, IC50 for A375 + M0 shCTRL2 was 18.67 µM, SKMEL28 + M0 shCTRL2 was 30.1 µM, WM2664 + M0 shCTRL2 was 66.37 µM). In contrast, tumor cells pre-co-cultured with IGF1R-deficient macrophages did not induce apparent resistance to PLX4032 even if co-culture had been conducted for three rounds (Fig. 3K–M, IC50 for A375 + M0 shIGF1R3 was 0.13 µM, SKMEL28 + M0 shIGF1R3 was 0.56 µM, WM2664 + M0 shIGF1R3 was 4.482 µM). In vivo, A375 cells pre-treated with IGF1R-intact macrophages formed larger tumors in nude mice than those pre-co-cultured with IGF1R-deficient macrophages (Fig. 3N), confirming the pro-tumorigenic role of intact IGF1R signaling on THP-1-derived TAMs. When treated with PLX4032, tumors derived from A375 cells educated with IGF1R-intact macrophages continued to grow despite treated with PLX4032, and the growth curves of tumor volumes showed significant differences during the tumor progression (Fig. 4A–C, **P < 0.01). Whereas tumors from IGF1R-deficient macrophage pre-educated cells remained more sensitive to PLX4032 (Fig. 4D–F, ***P < 0.001). Notably, no significant difference in tumor volumes was found between the PLX4032-treated and control group of A375 + M0 shIGF1R3 on day 14 following drug administration (Fig. 4D). These findings suggest that IGF1R-deficient macrophages merely delay the development of tumor resistance to PLX4032 rather than completely block its emergence. Histological examination revealed denser, more compact tissues in resistant tumors versus looser architecture in responsive ones (Fig. 4C, F). Above results showed that IGF1-IGF1R signaling in THP-1derived TAMs may affect the tumor-promoting abilities of TAMs. Fig. 4Knockdown of IGF1R in THP-1-derived macrophages affects the sensitivity of pre-co-cultured A375 cells to PLX4032. A Growth curves of A375 tumors from cells pre-co-cultured three times with THP-1-derived M0 shCTRL macrophages (A375+M0 shCTRL 3), treated with vehicle or PLX4032 (10 mg/kg) every two days (n=5). B Representative images of A375 tumors pre-co-cultured with M0 shCTRL macrophages. C HE staining of A375 tumors pre-co-cultured with M0 shCTRL macrophages. D Growth curves of A375 tumors from cells pre-co-cultured three times with THP-1-derived M0 shIGF1R macrophages (A375+M0 shIGF1R 3), treated with vehicle or PLX4032 (10 mg/kg) every two days (n=5). E Representative images of A375 tumors pre-co-cultured with M0 shIGF1R macrophages. F HE staining of A375 tumors pre-co-cultured with M0 shIGF1R macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Two-way ANOVA A, D. **P<0.01, ***P<0.001 Knockdown of IGF1R in THP-1-derived macrophages affects the sensitivity of pre-co-cultured A375 cells to PLX4032. A Growth curves of A375 tumors from cells pre-co-cultured three times with THP-1-derived M0 shCTRL macrophages (A375+M0 shCTRL 3), treated with vehicle or PLX4032 (10 mg/kg) every two days (n=5). B Representative images of A375 tumors pre-co-cultured with M0 shCTRL macrophages. C HE staining of A375 tumors pre-co-cultured with M0 shCTRL macrophages. D Growth curves of A375 tumors from cells pre-co-cultured three times with THP-1-derived M0 shIGF1R macrophages (A375+M0 shIGF1R 3), treated with vehicle or PLX4032 (10 mg/kg) every two days (n=5). E Representative images of A375 tumors pre-co-cultured with M0 shIGF1R macrophages. F HE staining of A375 tumors pre-co-cultured with M0 shIGF1R macrophages. The error bars represent the standard deviation. Statistical analysis was performed using Two-way ANOVA A, D. **P<0.01, ***P<0.001 IGF1-IGF1R signaling regulates ECM organization in TAMs To explore the molecular basis of IGF1R-dependent effects, we performed bulk RNA sequencing on THP-1 derived macrophages and A375 cells after co-culture. In IGF1R-deficient macrophages (TAMs_shIGF1R), 1260 genes were downregulated and 2142 upregulated compared to controls (Fig. 5A, B). Enrichment analysis identified “Extracellular matrix organization” as one of the top Reactome terms (Fig. 5C), along with “ECM-receptor interaction” in KEGG analysis (Fig. 5D). Key genes involved in collagen synthesis and matrix remodeling, such as COL4A1, COL4A2, ITGA1, and LAMB2, were differentially expressed (Fig. 5E). Fig. 5Transcriptome Analysis of THP-1-derived TAMs with IGF1R Deficiency. A Volcano plot showing differentially expressed genes in THP-1-derived TAMs transduced with shIGF1R versus shCTRL. |Log2(Fold Change)| ≥ 1, FDR < 0.05. B Heatmap of gene expression profiles comparing TAMs_shIGF1R and TAMs_shCTRL. C Reactome pathway enrichment analysis (bar plot) of TAMs_shIGF1R versus TAMs_shCTRL. D KEGG pathway enrichment analysis (bar plot) of TAMs_shIGF1R versus TAMs_shCTRL. E KEGG pathway enrichment analysis (dot plot) of TAMs_shIGF1R versus TAMs_shCTRL Transcriptome Analysis of THP-1-derived TAMs with IGF1R Deficiency. A Volcano plot showing differentially expressed genes in THP-1-derived TAMs transduced with shIGF1R versus shCTRL. |Log2(Fold Change)| ≥ 1, FDR < 0.05. B Heatmap of gene expression profiles comparing TAMs_shIGF1R and TAMs_shCTRL. C Reactome pathway enrichment analysis (bar plot) of TAMs_shIGF1R versus TAMs_shCTRL. D KEGG pathway enrichment analysis (bar plot) of TAMs_shIGF1R versus TAMs_shCTRL. E KEGG pathway enrichment analysis (dot plot) of TAMs_shIGF1R versus TAMs_shCTRL In A375 cells that underwent three rounds of pre-co-culture with THP-1-derived macrophages in the absence of PLX4032 treatment, 71 genes were upregulated and 136 genes were downregulated (Fig. 6A, B). Reactome analysis revealed strong enrichment of “Extracellular matrix organization,” “Collagen formation,” and “Degradation of extracellular matrix” in A375 cells which had pre-co-cultured with IGF1R shRNA interfered with TAMs (Fig. 6C). Chord plots highlighted MMP9, SERPINE1, LTB2, and BMP2 as key contributors to ECM remodeling (Fig. 6D). The dominant enrichment in “Extracellular matrix organization” underscores its central role in the observed phenotype (Fig. 6E). Fig. 6Transcriptome Analysis of A375 Cells Pre-co-cultured with TAMs_shIGF1R or TAMs_shCTRL. A Volcano plot showing differentially expressed genes in A375 cells pre-co-cultured with TAMs_shIGF1R versus TAMs_shCTRL. |Log2(Fold Change)| ≥ 1, FDR < 0.05. B Heatmap of gene expression profiles in A375 cells under TAMs_shIGF1R and TAMs_shCTRL co-culture conditions. C Bar plot of Reactome pathway enrichment analysis for differentially expressed genes in A375_TAMs_shIGF1R vs. A375_TAMs_shCTRL. D Chord plot visualizing Reactome pathway enrichment results for A375 cells co-cultured with TAMs_shIGF1R relative to TAMs_shCTRL. E Dot plot of Reactome pathway enrichment analysis comparing A375_TAMs_shIGF1R and A375_TAMs_shCTRL groups Transcriptome Analysis of A375 Cells Pre-co-cultured with TAMs_shIGF1R or TAMs_shCTRL. A Volcano plot showing differentially expressed genes in A375 cells pre-co-cultured with TAMs_shIGF1R versus TAMs_shCTRL. |Log2(Fold Change)| ≥ 1, FDR < 0.05. B Heatmap of gene expression profiles in A375 cells under TAMs_shIGF1R and TAMs_shCTRL co-culture conditions. C Bar plot of Reactome pathway enrichment analysis for differentially expressed genes in A375_TAMs_shIGF1R vs. A375_TAMs_shCTRL. D Chord plot visualizing Reactome pathway enrichment results for A375 cells co-cultured with TAMs_shIGF1R relative to TAMs_shCTRL. E Dot plot of Reactome pathway enrichment analysis comparing A375_TAMs_shIGF1R and A375_TAMs_shCTRL groups To further explore the regulatory effects of THP-1 derived TAMs and A375 melanoma cells on ECM, we analyzed the expression alterations of key ECM-related genes in both TAMs and A375 cells following IGF1R knockdown in macrophages using transcriptomic data. The results revealed that IGF1R silencing in THP-1 derived TAMs led to the upregulation of ECM-associated genes such as COL4A1, COL4A2, DMP1, ITGA1 and LAMB2 in macrophages (Fig. S3A). In contrast, melanoma cells co-cultured with these macrophages exhibited downregulated expression of pivotal ECM genes including COL22A1, COL5A1, COL6A3, CTSS and LAMB3 (Fig. S3B). Collectively, these findings demonstrated that macrophage-specific IGF1R knockdown disturbed ECM regulation in both macrophages and their co-cultured tumor cells, yet the underlying regulatory mechanisms may differ between the two cell types. IGF1R deficiency alters macrophage infiltration and collagen deposition in vivo Given the different mechanisms on ECM organization by THP-1derived macrophages and A375 tumor cells, we further investigated the ECM components in vivo. To better investigate the regulatory effect of macrophage-specific IGF1R deficiency on ECM within the TME, we employed a myeloid cell-specific IGF1R knockout mouse model. We implanted SMM102 melanoma cells into genetically modified mice with myeloid-specific IGF1R deletion [15]. Immunofluorescence staining of tumor sections showed increased F4/80⁺ macrophage infiltration and enhanced collagen IV deposition in tumors from IGF1R-deficient mice compared to controls (Fig. 7). This suggests that IGF1R deficiency in TAMs up-regulated the collagen deposition in vivo, while tumor cells regulated by the IGF1R deficient TAMs displayed faint regulation on ECM organization. Fig. 7Immunofluorescence analysis of SMM102 tumors in myeloid cell-specific IGF1R-deficient mice treated with DMSO vehicle or PLX4032 Immunofluorescence analysis of SMM102 tumors in myeloid cell-specific IGF1R-deficient mice treated with DMSO vehicle or PLX4032 Discussion Melanoma arises from the malignant transformation of melanocytes, primarily driven by mutations in the BRAF protein and subsequent hyperactivation of the MAPK signaling pathway. Current standard therapies, including targeted agents and immunotherapies, have significantly improved overall survival rates in patients with BRAF-mutant melanoma [1]. However, the development of acquired resistance remains a major clinical challenge, limiting therapeutic efficacy in a subset of patients. While intrinsic mechanisms of resistance within melanoma cells have been extensively studied, the TME comprising diverse cellular components and extracellular matrix elements has increasingly been recognized as a critical contributor to the emergence of resistance to both targeted and immunotherapeutic interventions [17]. Therefore, elucidating the molecular interactions between tumor cells and the TME is essential for identifying novel therapeutic strategies and predictive biomarkers in patients at high risk of developing drug resistance. Current therapeutic strategies for melanoma, including targeted therapy and immunotherapy, remain complex. Meanwhile, technologies such as genomic sequencing facilitate the development of personalized medication regimens in clinical practice. The canonical BRAF-mutant melanoma model and BRAF inhibitors are conducive to preliminary investigation into macrophage-mediated tumor regulation. In our research, we emphasized the pivotal roles of IGF1 in the context of drug resistance to targeted therapy in melanoma. Our findings demonstrate that IGF1 is essential for the polarization of THP-1-derived macrophages, with knockdown of its receptor IGF1R significantly or inhibition of IGF1R signaling pharmacologically downregulating polarization markers. Furthermore, utilizing co-culture systems and in vivo models, we characterized THP-1-derived TAMs as a pro-tumor model. IGF1R deficiency impaired their capacity to promote tumor progression, thereby reducing their ability to induce drug resistance of melanoma cells to BRAF inhibitors. The concurrent suppression of both M1- and M2-associated markers upon IGF1R knockdown or inhibition indicates that IGF1R signaling serves as a master regulator of macrophage polarization, rather than selectively biasing polarization toward a specific subset. This dual requirement is consistent with prior work showing that IGF1 is differentially secreted by polarized macrophages and that autocrine IGF1/IGF1R signaling sustains the activation state of both M1 and M2 macrophages under immunometabolic challenges [16]. In the context of tumor promotion, our observation that IGF1R deficiency attenuates the pro-tumor function of TAMs corroborates in vivo evidence from IGF1R-deficient mouse models, in which systemic deletion of IGF1R diminished tumor burden and lung metastasis [12]. Previous studies on mechanisms underlying resistance to targeted therapy in BRAF-mutant melanoma have predominantly focused on intrinsic alterations of tumor cells under drug pressure, such as cell-autonomous adaptations (ERK reactivation, NRAS upregulation, BRAF splice variants, MITF rewiring) [18]. IGF1R/PI3K signaling has been identified as a key bypass pathway in BRAFi-resistant melanoma, where tumor cells upregulate IGF1R to restore downstream survival signaling [19, 20]. Our data suggest that IGF1R signaling in TAMs indirectly contribute to drug resistance by educating tumor cells, albeit with a relatively moderate effect size. This finding is therapeutically significant, as it implies that targeting IGF1R specifically in the myeloid compartment may potentiate the efficacy of BRAF-targeted therapy. It is important to reconcile our findings with studies reporting seemingly opposite effects, wherein IGF1R loss in myeloid cells was associated with an M2-like phenotype. Eleftheria Ieronymaki et al. have reviewed that LysMCre-mediated molecules deletion in IGF1R signaling in macrophages led to upregulation of M2 markers [21]. However, several key distinctions should be noted. First, that study examined macrophages in the context of systemic insulin resistance and metabolic dysregulation, where compensatory hyperinsulinemia may activate insulin receptor (IR) signaling to sustain downstream PI3K/Akt pathways independently of IGF1R [22]. Indeed, IGF1R-targeted therapies in clinical trials have been hampered by feedback hyperinsulinemia and IR-A isoform upregulation, which re-activate pro-tumor signaling through IR/IGF1R hybrid receptors [23]. Second, the tissue microenvironment appears to dictate the functional outcome of IGF1R deficiency. While IGF1R deletion in CNS-resident macrophages exacerbated neuroinflammation [24], its deletion in the lung TME consistently reduced TAM-mediated immunosuppression and tumor progression [12]. These context-dependent differences underscore that the net effect of IGF1R ablation on macrophage function is determined by the interplay between cell-intrinsic signaling alterations and the surrounding cytokine/metabolic milieu. The mechanistic insight provided by transcriptomic analysis reveals that IGF1-IGF1R signaling governs extracellular matrix organization, a process essential for maintaining a supportive TME. Furthermore, aberrant ECM deposition and remodeling play a pivotal role in driving therapeutic resistance in BRAF-mutant melanoma. Resistant cells upregulate collagens, fibronectin, and ECM-remodeling enzymes (e.g., MT1-MMP) to activate integrin β1/FAK [25, 26], integrin α3β1/α11β1-Src-YAP1 [27], and DDR1/2-NIK/NF-κB2 pro-survival signaling [28]. ECM stiffness itself, sensed via Piezo1, integrins, and YAP/TAZ, drives a feedforward loop with M2-like TAMs that further deposit ECM [10]. The miR-143/−145 cluster- and USP9X-dependent mechanotransduction pathways reinforce this resistant state [29], while fibronectin-integrin ITGAV adhesion maintains senescence-associated tolerance [30]. TAMs directly remodel the ECM by secreting MMPs to facilitate tumor invasion and metastasis [31]. Additionally, TAMs contribute to ECM deposition by synthesizing collagen in response to stiffness and TGF-β signaling, promoting fibrosis and increased matrix stiffness [32]. This stiffness, in turn, polarizes TAMs toward a pro-tumor M2 phenotype via mechanoreceptors, creating a feedforward loop that enhances immune exclusion [10, 33, 34]. In our in vitro findings, knockdown of IGF1R enhanced the ability of collagen synthesis by THP-1-derived macrophages, with increasing expression of COL4A1 and COL4A2. This is consistent with immunofluorescence staining results of Collagen IV in xenograft tumors from mice with myeloid-specific IGF1R deficiency. We also found that A375 cells pre-co-cultured with IGF1R-deficient THP-1-derived macrophages retained sensitivity to PLX4032. Consistently, transcriptomic analysis of A375 cells revealed that genes associated with extracellular matrix organization and collagen formation were significantly downregulated following co-culture with IGF1R-deficient macrophages. However, the in vivo experiment in IGF1R-deficient genetic mice showed increased collagen deposition and macrophage infiltration. We attribute this discrepancy to the differences between the in vitro co-culture system and the in vivo tumor microenvironment in IGF1R-deficient mice. Nevertheless, we performed targeted knockout of IGF1R in macrophages. Compared with its indirect effect on modulating drug sensitivity in A375 cells within the co-culture system, the loss of this gene primarily drives the dysfunction of ECM remodeling in macrophages. In vivo assays revealed significantly elevated collagen deposition in the microenvironment of tumor cells co-cultured with IGF1R-deficient macrophages, accompanied by restored drug sensitivity of tumors. These findings indicate that the drug sensitivity of BRAF-mutant melanoma is predominantly determined by intrinsic properties of tumor cells, and macrophages exert a relatively weak regulatory effect on tumor cells in the early stage of tumor progression. These regulatory effects on ECM homeostasis carry critical implications for the clinical application of IGF1–IGF1R signaling inhibitors in tumor treatment. Limitations of this study include reliance on cell line models and limited patient sample validation. Further investigation in patient-derived organoids or xenografts would strengthen translational relevance. Additionally, exploring the impact of IGF1-IGF1R signaling on other immune cell types—such as T cells and neutrophils—could provide a more comprehensive understanding of the immune landscape in resistant tumors. In conclusion, this work identifies IGF1-IGF1R signaling in TAMs as a key regulator of extracellular matrix organization and therapy resistance in melanoma. It provides novel insights into resistance to tumor targeted therapy and informs the selection of combined targeted therapy regimens. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1